Hoping to fill what chief medical officer (CMO) Evan Loh called "a vacuum of unmet need" created by the FDA's recent edict on the dangers of fluoroquinolone antibiotics, Paratek Pharmaceuticals Inc. aims to build on success with the first of two phase III registration trials comparing its once-daily, broad-spectrum antibiotic, omadacycline, to linezolid (Zyvox, Pfizer Inc.) for acute bacterial skin and skin structure infection (ABSSSI).